Cited by 206Diabetes, Cardiovascular Risks, and LipoproteinsBlood Pressure and Hypertension StudiesDiabetes Treatment and Management

The DOI matches its Crossref record.

Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women

Giugliano, Dario, De Rosa, Nicoletta, Di Maro, Giosuè, Marfella, Raffaele, Acampora, Rita, Buoninconti, Raffaello, D'Onofrio, Felice·1993·Diabetes Care

DOI 10.2337/diacare.16.10.1387

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the effects of metformin on blood pressure, left ventricular mass, and some metabolic and endocrine parameters in nondiabetic, obese, hypertensive women. RESEARCH DESIGN AND METHODS: Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. All patients were hospitalized 4 times, i.e., before randomization and after each treatment (metformin or placebo), to conduct metabolic and cardiovascular investigations (oral glucose tolerance test, euglycemic clamp associated with indirect calorimetry, and echocardiography). RESULTS: Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. CONCLUSIONS: These findings suggest that metformin treatment in obese, nondiabetic, hypertensive women produces a more favorable cardiovascular risk profile.

Integrity signals

Registry

Crossref · 10.2337/diacare.16.10.1387

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 205

Metabolic consequences of hyperglycemia and insulin resistance
Jellinger, P. S. (2009) · Insulin · doi:10.1016/s1557-0843(09)80003-1 · Cited by 30
Disparate effects of antidiabetic drugs on arterial contraction
Peuler, J. D., Miller, J. A., Bourghli, M., Zammam, H. Y., Soltis, E. E., & Sowers, J. R. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90217-1 · Cited by 30
Metformin relaxes rat tail artery by repolarization and resultant decreases in Ca2+ influx and intracellular [Ca2+]
Chen, X.-L., Panek, K., & Rembold, C. M. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715030-00008 · Cited by 28
Metformin and Carbohydrate-Modified Diet: A Novel Obesity Treatment Protocol
Mogul, H. R., Peterson, S. J., Weinstein, B. I., Zhang, S., & Southren, A. L. (2001) · Heart Disease · doi:10.1097/00132580-200109000-00002 · Cited by 27
Metformin Attenuates Salt-Induced Hypertension in Spontaneously Hypertensive Rats
Muntzel, M. S., Hamidou, I., & Barrett, S. (1999) · Hypertension · doi:10.1161/01.hyp.33.5.1135 · Cited by 27
CARDIOVASCULAR EFFECTS OF ORAL HYPOGLYCAEMIC DRUGS
Howes, L. G., Sundaresan, P., & Lykos, D. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb02596.x · Cited by 27
Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance
Scheen, A. J., Letiexhe, M. R., & Lefèbvre, P. J. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00410.x · Cited by 27
Metformin treatment leads to an increase in basal, but not insulin‐stimulated, glucose disposal in obese patients with impaired glucose tolerance
Morel, Y., Golay, A., Perneger, T., Lehmann, T. N., Vadas, L., Pasik, C., & Reaven, G. M. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00120.x · Cited by 26
Irreversibility of the Defect in Glycogen Synthase Activity in Skeletal Muscle From Obese Patients With NIDDM Treated With Diet and Metformin
Damsbo, P., Hermann, L. S., Vaag, A. A., Nielsen, O. H., & Beck‐Nielsen, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1489 · Cited by 25
“Metformin inhibits hepatic gluconeogenesis (14,15) and increases muscular glucose uptake (16,17) and glucose oxidation (15,18).”
BackgroundResult
Efficacy of metformin in the management of periodontitis: A systematic review and meta-analysis
Najeeb, S., Zafar, M. S., Khurshid, Z., Zohaib, S., Madathil, S. A., Mali, M., & Almas, K. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2018.02.029 · Cited by 22
“Moreover, MF is the drug of choice to treat type 2 diabetes mellitus in obese patients (Giugliano et al., 1993).”
Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity
Zhang, C., Gao, F., Luo, H., Zhang, C., & Zhang, R. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0240-1 · Cited by 22
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.2073 · Cited by 22
AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.01.044 · Cited by 22
“This has indeed been reported in some clinical studies [77,78], but not in others [79–81].”
Result
PREVENTION OF TYPE 2 DIABETES
Goldberg, R. B. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70025-0 · Cited by 21
Prevention of Type 2 Diabetes
Charles, M.-A. A., & Eschw??ge, E. (1999) · Drugs · doi:10.2165/00003495-199958001-00015 · Cited by 21
Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin
Chamarthi, B., Ezrokhi, M., Rutty, D., & Cincotta, A. H. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1243003 · Cited by 20
“ginine [61], advanced glycated end products [62], endothelin1 [63] and sympathetic tone [64,65] can lead to improvement of endothelial dysfunction and cardiomyocyte physiology by molecular means that may positively interact with the effects of B-QR described above on the neuroendocrine regulation of vascular biology (…”
Background
Sulfenamide and sulfonamide derivatives of metformin can exert anticoagulant and profibrinolytic properties
Markowicz-Piasecka, M., Huttunen, K. M., Mateusiak, Ł., Mikiciuk‐Olasik, E., & Sikora, J. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.012 · Cited by 20
Effect of metformin on the vascular and glucose metabolic actions of insulin in hypertensive rats
Santuré, M., Pǐtre, M., Gaudreault, N., Marette, A., Nadeau, A., & Bachelard, H. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.5.g682 · Cited by 20
“Improvement in insulin sensitivity with parallel reduction in blood pressure have been reported in nonobese nondiabetic untreated hypertensive patients (19), in obese diabetic and nondiabetic hypertensive women (11, 12), and in normotensive patients with type II diabetes (4).”
BackgroundResult
The influence of insulin‐like Growth Factor‐1‐Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis
Engels, C. C., de Glas, N. A., Sajet, A., Bastiaannet, E., Smit, V. T. H. B. M., Kuppen, P. J. K., Seynaeve, C., van de Velde, C. J. �., & Liefers, G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.010 · Cited by 18
Troglitazone and Metformin, But Not Glibenclamide, Decrease Blood Pressure in Otsuka Long Evans Tokushima Fatty Rats
Kosegawa, I., Chen, S., Awata, T., Negishi, K., & Katayama, S. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909068661 · Cited by 18
Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice
Dorvash, M., Khoshnoud, M. J., Saber, H., Dehghanian, A., Mosaddeghi, P., & Firouzabadi, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.002 · Cited by 18
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study
Gregorio, F., Ambrosi, F., Manfrini, S., Santucci, A., & Filipponi, P. (1997) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00047-8 · Cited by 17
The effects of metformin on cardiovascular risk factors
Grant, P. J. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110507 · Cited by 18
Do effects on blood pressure contribute to improved clinical outcomes with metformin?
Schäfers, R. F. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72789-x · Cited by 18
“One small study included a detailed evaluation of the effects of metformin on the activity of the sympathetic nervous system in insulin-resistant hypertensive men, and did not reveal any significant effect of metformin on sympathetic nerve activity [39], while another study demonstrated a slight decrease in plasma cat…”
Background
Effects of metformin in obese patients with impaired glucose tolerance
Scheen, A. J., Letiexhe, M. R., & Lefèbvre, P. J. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110511 · Cited by 17
Metformin Inhibits Ganglionic Neurotransmission in Renal Nerves
Petersen, J. S., Liu, W., Kapusta, D. R., & Varner, K. J. (1997) · Hypertension · doi:10.1161/01.hyp.29.5.1173 · Cited by 17
Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats
Peuler, J. D. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00051-6 · Cited by 17
Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes
Skibitskiy, V. V., Gutova, S. R., Фендрикова, А. В., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.4.n1112 · Cited by 16
Tratamento de Diabetes e Hipertensão no Paciente Obeso
Faria, A. N., Zanella, M. T., Kohlman, O., & Ribeiro, A. B. (2002) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302002000200004 · Cited by 16
Commonly used endocrine drugs
Rosa, M. M., & Dias, T. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00054-1 · Cited by 16
Is Metformin Cardioprotective?
Sasali, A., & Leahy, J. L. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.243 · Cited by 16
“Why? One could speculate it reflects the known CV benefits of metformin over sulfonylureas, less weight gain and lowered triglyceride levels (8,9), and the resulting effects on potential CV pathogenic mechanisms such as plasminogen activator inhibitor-1 (10).”
Background
Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.
Chen, C., Wang, H., Shih, H.-C., Sheen, L., Chang, C., Chen, R.-H., & Wang, T.-Y. (2001) · PubMed · Cited by 16
Effects of fibric acid derivatives and metformin on postprandial lipemia
Weintraub, M. S., Charach, G., & Grosskopf, I. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00221-4 · Cited by 16
Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
Joshi, S. (2005) · PubMed · Cited by 15
"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics
Yajima, K., Shimada, A., Hirose, H., Kasuga, A., & Saruta, T. (2004) · The Review of Diabetic Studies · doi:10.1900/rds.2004.1.89 · Cited by 14
“Rev Diabetic Stud (2004) 1:89-94 Copyright © by The SBDR blood pressure levels [5, 16-21], although it is not concluded whether the effect depends on glucose metabolism or not.”
Background
Effect of Low Glycemic Index Diet Versus Metformin on Metabolic Syndrome
Rajabi, S., Mazloom, Z., Zamani, A., & Tabatabaee, H. R. (2015) · Intern J Endocrinol Metab · doi:10.5812/ijem.23091 · Cited by 15
“Metformin has also been shown to have beneficial effects on insulin sensitivity and glucose metabolism, which has been documented in the literature since 1993 (20, 21).”
Result
The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism
Harris, K., Desai, N., Gupta, M., Xue, X., Chatterjee, P. K., Rochelson, B. L., & Metz, C. N. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0115-9 · Cited by 15
“Metformin improves hepatic lipid metabolism [19, 20].”
Background
Metformin: Mechanisms of Antihyperglycemic Action,Other Pharmacodynamic Properties, and Safety Perspectives
Garber, A. J. (1997) · Endocrine Practice · doi:10.4158/ep.3.6.359 · Cited by 15
New Pharmacological Approaches to Insulin and Lipid Metabolism
Petrie, J. R., & Donnelly, R. (1994) · Drugs · doi:10.2165/00003495-199447050-00001 · Cited by 15
From apelin to exercise: emerging therapies for management of hypertension in pregnancy
Gilbert, J. S. (2017) · Hypertension Research · doi:10.1038/hr.2017.40 · Cited by 14
Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats
Apaijai, N., Jinawong, K., Singhanat, K., et al. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0134 · Cited by 14
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes
Prato, S. D., & Volpe, L. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1411 · Cited by 14
“Moreover, metformin reduces arterial blood pressure in obese hypertensive individuals [71], although no effect was observed in lean hypertensive patients [72].”
Background
Intracerebroventricular metformin attenuates salt-induced hypertension in spontaneously hypertensive rats
Petersen, J. S. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02220-8 · Cited by 13
Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients
Kawano, Y., Okuda, N., Minami, J., Takishita, S., & Omae, T. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018100-00013 · Cited by 13
Pulse pressure and diabetes treatments
Alemi, H., Khaloo, P., Mansournia, M. A., Rabizadeh, S., Salehi‍, S. S., Mirmiranpour, H., Meftah, N., Esteghamati, A., & Nakhjavani, M. (2018) · Medicine · doi:10.1097/md.0000000000009791 · Cited by 12
Insulin Action and Endothelial Function
Mather, K. J., Baron, A., & Quon, M. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_7 · Cited by 12
Antihyperalgesic Effects of Indomethacin, Ketorolac, and Metamizole in Rats: Effects of Metformin
Guzmán‐Priego, C. G., Méndez-Mena, R., González, M. A. B., et al. (2017) · Drug Development Research · doi:10.1002/ddr.21379 · Cited by 12
“Metformin is a biguanide drug that is widely used in the treatment of hyperglycemia either as monotherapy or in combination with sulfonylureas to treat diabetic patients [Giugliano et al., 1993].”
Background
Clinical Pharmacology of Biguanides
Hermann, L. S. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-09127-2_14 · Cited by 11
Insulin Resistance: Site of the Primary Defect or how the Current and the Emerging Therapies Work
Kolaczynski, J. W., & Caro, J. F. (1998) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.1998.9.2-4.281 · Cited by 12
Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease
Carlsen, S. M., Grill, V., & Følling, I. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00121-6 · Cited by 11
Metformin Modifies the Exercise Training Effects on Risk Factors for Cardiovascular Disease in Impaired Glucose Tolerant Adults
Malin, S. K., Nightingale, J., Choi, S.-E., Chipkin, S. R., & Braun, B. (2012) · Obesity · doi:10.1038/oby.2012.133 · Cited by 11
Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats
Tan, Z., Xu, Z., Gui, Q., Wu, W., & Yang, Y. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132950 · Cited by 10
“Metformin appears to have beneficial effects on blood lipoproteins by reducing LDL-C(13,14) and may increase HDL-C levels.(14) The changes of serum lipid levels may be a reason to explain why the vascular lesion in the metformin group was slighter than that in the gliquidone.”
Background
Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial
Correa, V., Fuchs, F. D., Schaan, B. D., Moreira, L. B., Fuchs, S. C. P. C., & Gus, M. (2018) · Endocrine · doi:10.1007/s12020-018-1722-1 · Cited by 12
Insulin-sensitising agents
Perry, C. G., & Petrie, J. R. (1998) · Emerging Drugs · doi:10.1517/14728214.3.1.247 · Cited by 10
Insulin resistance, a result of reduced synthesis of prostaglandylinositol cyclic phosphate, a mediator of insulin action?
Wasner, H. K., Salge, U., Psarakis, E., & Niktopoulos, A. (1997) · Acta Diabetologica · doi:10.1007/s005920050085 · Cited by 11
Response to Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867
Brandmaier, S., Xu, T., Illig, T., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0022 · Cited by 8
“(3) is based on the investigation of 12 obese hypertensive women without diabetes; therefore, the underlying design is different from ours (2).”
Background
Metformin and Other Biguanides: Pharmacology and Therapeutic Usage
Garber, A. J. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0610 · Cited by 8
Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858–1867
Sonne, D. P., & Knop, F. K. (2015) · Diabetes Care · doi:10.2337/dc15-1794 · Cited by 8
“effects of metformin have long been recognized (2).”
Background
Development and implementation of signs- and symptoms-based insulin adjustment algorithm
Lee, J. V., & Wong, S. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100032 · Cited by 7
The influence of chromosome 4 on metabolism and spatial memory in SHR and SLA16 rat strains
Velázquez, A. M., Roversi, K., Dillenburg-Pilla, P., Rodrigues, R. F., Zárate-Bladés, C. R., Prediger, R. D., & Izídio, G. S. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111966 · Cited by 6
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
Peuler, J. D., & Phelps, L. E. (2015) · Journal of Smooth Muscle Research · doi:10.1540/jsmr.51.22 · Cited by 6
Comparative evaluation of effects of combined oral anti-diabetic drugs (sulfonylurea plus pioglitazone and sulfonylurea plus metformin) over lipid parameters in type 2 diabetic patients
Sen, S., Sinha, S., & Gupta, K. K. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130605 · Cited by 6
A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up
Paczkowska, A., Hoffmann, K., Michalak, M., Bryl, W., Kopciuch, D., Zaprutko, T., Ratajczak, P., Nowakowska, E., & Kus, K. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s317659 · Cited by 7
“In the double-blind, cross-over, randomized studies performed by Giugliano et al after 12 weeks of treatment using only metformin among obese, hypertensive women, a significant decrease of following parameters were observed: fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventri…”
Background
Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification?
Pinkston, M. M., Poston, W. S. C., Reeves, R. S., Haddock, C. K., Taylor, J. E., & Foreyt, J. P. (2006) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/bf03327751 · Cited by 6
Uso de hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2
Gómez‐García, A., Paniagua, J. G., & Aguilar, C. Á. (2005) · Atención Primaria · doi:10.1157/13074292 · Cited by 6
Fibrinolytic activity in Nigerian diabetics
Adediran, I. A., Ikem, R. T., & Borisade, M. F. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.017996 · Cited by 6
A metformin hatása a vérzsírértékekre, illetve a szív és érrendszeri kockázatra sztatinkezelésben nem részesülő 2-es típusú cukorbetegekben
Κender, Ζ., Groener, J. B., Reismann, P., & Kopf, S. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31547 · Cited by 6
“[38] Giugliano D, De Rosa N, Di Maro G, et al.”
Background
Insulin sensitivity with respect to glucose metabolism in hypertension-prone men did not predict the blood pressure increase in 5 years
Mattiasson, I., Endre, T., & Hulthén, U. L. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001272 · Cited by 5
Effect of Metformin on Blood Pressure
Kantola, I. M., Rouru, J., Malminiemi, K., Arkkila, P., Korhonen, K., Rantanen, S., & Huupponen, R. (2002) · Clinical Drug Investigation · doi:10.2165/00044011-200222060-00001 · Cited by 4
“[29] The number of patients in our study was quite low, but similar to the numbers in former studies[15-18] that did not use 24-hour ambulatory blood pressure measurement.”
BackgroundResult
Potential vascular α1-adrenoceptor blocking properties of metformin in rat aorta and tail artery
Álvarez-Cámara, J. F., Ramirez-Rosas, M. B., Medina-Terol, G. J., Silva‐Velasco, D. L., Velazco-Paz, A., Sánchez‐López, A., Guzmán‐Priego, C. G., Osuna‐Martínez, U., & Centurión, D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172498 · Cited by 4
Cardiovascular Complications of Insulin Resistance
Bloomgarden, Z. T. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.305 · Cited by 4
Hipertensión arterial refractaria
Pinilla, C. F., & Cerrillo, M. R. (2000) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(00)71027-0 · Cited by 4
Effect of metformin on liver insulin metabolism and regional blood flow
Signore, A., Fiore, V., Chianelli, M., Ronga, G., & Pozzilli, P. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110504 · Cited by 4
Effects of oral antidiabetic drugs over lipid parameters in Turkish type 2 diabetes patients
Çağatay, P., Duman, B. S., Alasya, H., & Ipbüker, A. (2009) · Acta Medica Academica · Cited by 3
Lipid Lowering Effect of Anti Diabetic Agents-Recent Research
Pavithra, N., & Chaitanya, M. (2015) · International journal of pharma research and review · Cited by 3
Pharmacological evidence that metformin blocks the vasopressor responses mediated by stimulation of α 1 - and α 2 -adrenoceptors in pithed rats
de la Cruz, S. H., Medina-Terol, G. J., Beltran‐Ornelas, J. H., Gomez, C. B., Morato-Valderrama, Y., Sánchez‐López, A., & Centurión, D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.032 · Cited by 3
Cardiovascular Actions of Chronic Intracerebroventricular Administration of Metformin in Normotensive Rats
Andersen, D., Haugan, K., Sørensen, A.-M. L., Christensen, S., & Petersen, J. S. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00023.x · Cited by 3
Effects of troglitazone on coagulation—fibrinolysis abnormalities in patients with type II diabetes mellitus
Kubo, K. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85093-5 · Cited by 3
Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents
Chu, J. W., Abbasi, F., McLaughlin, T., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00284.x · Cited by 3
Metformin
Stümvoll, M., Häring, H., & Matthaei, S. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-10 · Cited by 2
Comparison of a generic and a brand metformin products in type II diabetes: A double blind randomized clinical trial study
Tabatabaei‐Malazy, O., Heshmat, R., Taheri, E., et al. (2007) · DARU Journal of Pharmaceutical Sciences · Cited by 2
Obesity, Diabetes, and Hypertension
Tan, A. S., Brietzke, S., Gardner, D. W., & Sowers, J. R. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_10 · Cited by 2
Effect of Oral Antidiabetics and Insulin on Lipids and Coronary Heart Disease in Non‐Insulin‐dependent Diabetes Mellitus
Hanefeld, M., Temelkova-Kurktschiev, T. S., & Köhler, C. U. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb51839.x · Cited by 2
Reflexiones sobre la hiperinsulinemia en la hipertensión arterial
Galvañ, V. G., & Mas, J. R. I. (2002) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(02)71240-3 · Cited by 2
Dietary metformin effects on in vitro and in vivo metabolism in the chicken
Rosebrough, R. W., & Ashwell, C. M. (2005) · Nutrition Research · doi:10.1016/j.nutres.2005.03.001 · Cited by 1
“Similar results were found in obese, hypertensive women [18] and obese, type II diabetics in which the reduction of blood pressure was related to the antihyperglycemic effect [19].”
Result
EFFECT OF BETAHISTINE AND METFORMIN ON LIPID PROFILE IN OBESE FEMALES IN IRAQ: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
Al-Anbari, H. H., Al-Zubaidy, A. A., & Khazaal, F. A. K. (2017) · Iraqi journal of Medical Sciences · doi:10.22578/ijms.14.4.5 · Cited by 1
The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress
Reynolds, L., & GENUTH, S. M. (2018) · Diabetes Care · doi:10.2337/dci17-0021 · Cited by 1
“ing descriptions of the efficacy of metformin (34) and a report on the efficacy and safety of glimepiride, a modern sulfonyl-”
Background
Impact of Ramadan Fasting on Metabolic Syndrome Criteria: Among Treated Hypertensive and Diabetic Females of Halabja
Farag, H. A. M. (2022) · Kurdistan Journal of Applied Research · doi:10.24017/science.2022.1.11 · Cited by 1
“Study shows that metformin significantly decreases BP in non-diabetic hypertensive obese [35], and Improving insulin sensitivity by metformin during Ramadan fasting decreases BP in untreated hypertensive nonobese [36].”
Background
Syndrome X and diabetes: What is the mystery?
Weiswasser, J. M., Nylén, E., Arora, S., Wakefield, M., & Sidawy, A. N. (2002) · Seminars in Vascular Surgery · doi:10.1016/s0895-7967(02)70021-5 · Cited by 1
Metformin and/or Exercise Training Affect Metabolic Health in Men and Women with Prediabetes
Malin, S. K. (2011) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/2175194
Pharmacological means of influencing insulin resistance (a review)
Lipson, V. V. (1999) · Pharmaceutical Chemistry Journal · doi:10.1007/bf02508705
Novel modalities for preeclampsia prevention: A role for exercise training and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) administration
Banek, C. T. (2014) · Scholars' Bank (University of Oregon)
Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease
Krikorian, A., & Chaiban, J. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_12
EVIDENCES - THREE PRONGED DEFENSE OF BODY AGAINST CANCER CELLS RESULTING IN CARDIAC, METABOLIC AND AUTO-IMMUNE DISORDERS
Dosaj, S., Sharma, R. K., Dosaj, U., & Basement, M. P. (2012)
Effects of Metformin on Glycaemic Control and Cardiovascular Risk in Type 2 Diabetes
Perriello, G. (2003) · Springer eBooks · doi:10.1007/978-3-642-59352-9_6
Rational Treatment of the “Plurimetabolic Syndrome”
Tiengo, A., Avogaro, A., & Prato, S. D. (1995) · Medical science symposia series · doi:10.1007/978-94-011-0039-7_23
Implantación de la determinación de hemoglobina glucosilada capilar en un Área de Salud: estudio multicéntrico sobre evolución de pacientes con diabetes mellitus de tipo 2
Núñez‐Sánchez, M. Á., Cervantes-Cuesta, M. Á., Brocal-Ibañez, P., Salmerón-Arjona, E., León-Martínez, L. P., & Cerezo-Sanmartin, M. (2016) · Revista de Calidad Asistencial · doi:10.1016/j.cali.2016.09.005
RESEARCH PAPER Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension
Agard, C., Rolli‐Derkinderen, M., Sagan, C., Loirand, G., & Pacaud, P. (2009)
Cardiovascular effects of metformin on left ventricular hypertrophy in nondiabetic patients with coronary artery disease
Mohan, M. (2019) · Discovery Research Portal (University of Dundee)
Effects of Oral Hypoglycemic Drugs on Serum Lipid Profile in Hyperlipidemic Rats
Al-Jabouri, N. H. M. (2013) · Medical Journal of Babylon

Authors: Giugliano, D., De Rosa, N., Di Maro, G., Marfella, R., Acampora, R., Buoninconti, R., & D'Onofrio, F.
Affiliations: University of Campania "Luigi Vanvitelli" (IT)
Department of Gerontology and Metabolic Diseases, Second University of Naples Naples, Italy
ORCID: Giugliano, Dario
Marfella, Raffaele
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 1993-10-01
Volume: 16
Issue: 10
Pages: 1387-1390
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.16.10.1387
OpenAlex: W2039851346
Cited by: 206
References: 0
Citations by year: 2026: 1 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 9 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 3
FWCI: 5.86
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: metformin, hypertension, obesity, women, glucose metabolism, insulin sensitivity, blood pressure, left ventricular mass, lipid metabolism, cardiovascular risk, non-diabetic patients, fibrinogen, HDL cholesterol
MeSH terms: Blood Glucose, Blood Pressure, Calorimetry, Cholesterol, Double-Blind Method, Echocardiography, Female, Fibrinogen, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Hypertension, Insulin, Metformin, Middle Aged, Obesity, Triglycerides, Glucose Clamp Technique

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks